drugset / Trial / NCT00702481
Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer
Phase 2
Completed
32 enrolled
National Cancer Centre, Singapore
Innogene Kalbiotech Pte. Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to define the response and toxicities with the addition of Nimotuzumab to chemoradiation for head and neck cancer.
Timeline
- Start
- 2008-04-28
- Primary completion
- 2019-09-03
- Completion
- 2019-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 200 mg | — |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | — |